PIK3CA
2 drugsPhosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
Predictive biomarker for patient selection in 2 indications
Understanding PIK3CA
What it means: PIK3CA mutations activate the PI3K pathway, promoting cell growth and survival. Found in ~40% of HR+ breast cancers.
Why it matters: PI3K inhibitor alpelisib (combined with fulvestrant) approved for PIK3CA-mutated HR+/HER2- breast cancer.
Testing: Tested via NGS or PCR on tumor tissue or ctDNA. FDA-approved companion diagnostic available.
2
Approved Drugs
2
Indications
1
Companies
PIK3CA is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 1 company, spanning 2 indications including Breast Cancer, PIK3CA-Related Overgrowth Spectrum. Explore the targeted therapies, indications, testing methods, and companies developing PIK3CA drugs below.
Search PIK3CA Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PIK3CA
PIK3CA Indications
Breast Cancer PIK3CA-Related Overgrowth Spectrum